TriNav infusion system

Y90 Mapping Procedure using TriNav in Patient with Metastatic Neuroendocrine Tumor

SUMMARY: Patient with metastatic neuroendocrine tumor referred for Y90 treatment. The MAA mapping procedure was performed using the TriNav Infusion System, which successfully navigated to the target anatomy (Images 1-3). Post-procedural SPECT-CT imaging demonstrates intense uptake of the MAA within the tumor (Image 4) when delivered to the 1.5mm vessel (X1). These images highlight TriNav's trackability and how its SmartValve[™] can anchor in the vessel to allow for targeted delivery, even in challenging anatomy.



Image 1: Pre-procedural angiography shows 2 target vessels X1 and X2 (1.5mm and 1.9mm respectively) with sharp turns.



Image 2: TriNav successfully delivered around sharp turn into 1.9mm vessel (X2) during mapping angiography.



Image 3: Mapping angiography shows the TriNav successfully navigating the sharp turn to anchor the SmartValve in the target 1.5mm vessel (X1). Good tumor blush is observed, and the MAA is delivered via the TriNav in this position.



Image 4: Postprocedural SPECT-CT imaging demonstrates on-target delivery of the MAA via the 1.5mm artery and intense tumor uptake.

This content is sponsored by TriSalus Life Sciences®. Results are not predictive of outcomes in other cases.

INTENDED USE: The TriNav Infusion System is intended for use in angiographic procedures. It delivers radiopaque media and therapeutic agents to selected sites in the peripheral vascular system. CONTRAINDICATIONS: TriNav is not intended for use in the vasculature of the central nervous system (including the neurovasculature) or central circulatory system (including the coronary vasculature). Rx ONLY. For the safe and proper use of the TriNav device, refer to the Instructions for Use.





© 2021 TriSalus Life Sciences®. All rights reserved. MKT-0357 R01